PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.10
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
-5.38
Net cash position while TRVN shows net debt of 2.38. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-2.74
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
1.82
Current ratio 75-90% of TRVN's 2.42. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.